Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Intuitive Surgical (ISRG US): 1Q22 Review- Procedure Volume Growth Overshadowed by Macro Headwinds

Intuitive Surgical (ISRG US): Q2 2022 Results Missed Expectations; Raised Procedure Growth Guidance

Intuitive Surgical (ISRG US): Better-Than-Expected Q3 2022 Results; Raised Procedure Growth Guidance

Intuitive Surgical (ISRG US): Global Leadership to Continue Amid Upcoming Competition

Equity Bottom-Up

<p>Intuitive Surgical announced better-than-expected Q3 results, with revenue and EPS modestly beating consensus. Worldwide de Vinci procedures grew 20% y/y, despite negative impact from the resurgence of the COVID-19 in the U.S. The company reduced higher end of its 2021 procedure growth guidance by 100 basis points to 27–29% from 27–30% earlier. da Vinci system placement grew 72% y/y to 336, which should further augment procedure growth. Further delay in surgical robot launch by Johnson &amp; Johnson enhances our conviction on continuation of Intuitive's leadership positioning. </p>

Intuitive Surgical announced better-than-expected Q3 results, with revenue and EPS modestly beating consensus. Worldwide de Vinci procedures grew 20% y/y, despite negative impact from the resurgence of the COVID-19 in the U.S. The company reduced higher end of its 2021 procedure growth guidance by 100 basis points to 27–29% from 27–30% earlier. da Vinci system placement grew 72% y/y to 336, which should further augment procedure growth. Further delay in surgical robot launch by Johnson &amp; Johnson enhances our conviction on continuation of Intuitive's leadership positioning. 

Intuitive Surgical (ISRG US): Q3 Results Beat Consensus, Procedure Growth at Pre-Pandemic Level